ISIN | LU2334253387 |
---|---|
Valor Number | |
Bloomberg Global ID | |
Fund Name | Bellevue Healthcare Strategy U2 EUR |
Fund Provider |
Bellevue Asset Management AG
Zürich, Switzerland Phone: +41 44 267 67 00 E-Mail: info@bellevue.ch Web: www.bellevue.ch |
Fund Provider | Bellevue Asset Management AG |
Representative in Switzerland |
Waystone Fund Services (Switzerland) SA Lausanne Phone: 0041213111781 |
Distributor(s) |
Bank am Bellevue AG Küsnacht Phone: +41 44 267 67 67 |
Asset Class | Equities |
EFC Category | |
Distribution Policy | Accumulation |
Home Country | Luxembourg |
Issuing Condition | Combination of issuing commission charged by the fund management company and transaction fee charged by the fund |
Redemption Condition | Combination of redemption commission charged by the fund management company and transaction fee charged by the fund |
Investment Strategy *** | The Sub-fund is an actively managed equity fund. It is based on the Bellevue Healthcare Strategy that has been in existence since 2007. The investment objective of the sub-fund is to achieve long-term capital growth by investing at least two-thirds of the net assets of Bellevue Healthcare Strategy in a portfolio of carefully chosen shares and other equity securities of companies in the healthcare industry, or companies whose main activity consists of holding shares in such companies or financing such companies and who have their registered office or carry out the majority of their economic activity in recognised countries. |
Peculiarities |
Current Price * | 128.16 EUR | 15.11.2024 |
---|---|---|
Previous Price * | 129.78 EUR | 14.11.2024 |
52 Week High * | 133.46 EUR | 30.08.2024 |
52 Week Low * | 115.56 EUR | 29.11.2023 |
NAV * | 128.16 EUR | 15.11.2024 |
Issue Price * | ||
Redemption Price * | ||
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 383,756,168 | |
Unit/Share Assets *** | ||
Trading Information SIX |
YTD Performance | +7.74% |
29.12.2023 - 15.11.2024
29.12.2023 15.11.2024 |
---|---|---|
YTD Performance (in CHF) | +8.61% |
29.12.2023 - 15.11.2024
29.12.2023 15.11.2024 |
1 month | -2.64% |
15.10.2024 - 15.11.2024
15.10.2024 15.11.2024 |
3 months | -1.35% |
16.08.2024 - 15.11.2024
16.08.2024 15.11.2024 |
6 months | +1.60% |
15.05.2024 - 15.11.2024
15.05.2024 15.11.2024 |
1 year | +10.14% |
15.11.2023 - 15.11.2024
15.11.2023 15.11.2024 |
2 years | +0.51% |
15.11.2022 - 15.11.2024
15.11.2022 15.11.2024 |
3 years | -3.20% |
15.11.2021 - 15.11.2024
15.11.2021 15.11.2024 |
5 years | -0.08% |
15.06.2021 - 15.11.2024
15.06.2021 15.11.2024 |
Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
Insulet Corp | 3.93% | |
---|---|---|
Boston Scientific Corp | 3.49% | |
Vertex Pharmaceuticals Inc | 3.37% | |
HCA Healthcare Inc | 3.32% | |
Eli Lilly and Co | 3.21% | |
Penumbra Inc | 3.20% | |
UCB SA | 3.19% | |
UnitedHealth Group Inc | 3.16% | |
Stryker Corp | 3.09% | |
McKesson Corp | 2.71% | |
Last data update | 31.10.2024 |
TER | 0.92% |
---|---|
TER date | 29.01.2021 |
Performance Fee *** | |
PTR | |
Max. Management Fee *** | 0.60% |
Ongoing Charges *** | 0.96% |
SRRI ***
|
|
SRRI date *** | 31.10.2024 |
Low Carbon Designation *** | |
---|---|
ESG Rating Overall *** | |
ESG Rating Corporate *** | |
ESG Rating Sovereign *** | |
% AuM H&S Controversies *** |
Avg Carbon Risk Score *** | |
---|---|
Avg Carbon Risk Cat Avg *** | |
% AuM Covered Carbon *** | |
Avg Fossil Fuel Exposure *** | |
Fossil Fuel Cat Avg *** |
Strategy Level 1 *** | |
---|---|
Strategy Level 2 *** | |
Strategy Level 3 *** | |
Exclusions Level 1 *** | |
Exclusions Level 2 *** |